#USA #Washington #Danaher Corporation #DHR #quarterly results

Danaher Reports Third Quarter 2025 Results

Danaher Corporation (NYSE: DHR) has announced its financial performance for the quarter ending September 26, 2025, showcasing a robust growth story. The company reported net earnings of $908 million, translating to $1.27 per diluted share. Non-GAAP adjusted diluted net earnings were $1.89, indicating a promising financial landscape for the corporation.

In terms of revenue, Danaher experienced an increase of 4.5% year-over-year, bringing total sales to $6.1 billion. Specifically, non-GAAP core revenue also saw a growth of 3.0%, highlighting the effectiveness of Danaher’s operational strategies. The operating cash flow stood at $1.7 billion, while the non-GAAP free cash flow amounted to $1.4 billion.

Rainer M. Blair, President and CEO of Danaher, expressed optimism regarding the company's performance. He noted, "We are encouraged by our third quarter results. DBS-driven execution paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid enabled us to exceed our revenue, earnings, and cash flow expectations."

Blair further emphasized the company’s commitment to delivering value to customers, associates, and shareholders, reflecting a strategic focus on breakthrough innovation and productivity improvements that aim to enhance Danaher’s competitive standing in the market.

For the full fiscal year 2025, Danaher has opted not to reconcile Non-GAAP forecasted core sales growth and adjusted diluted net earnings per share with their respective GAAP measures, citing complications due to various elements such as currency exchange impacts and acquisition-related intangible asset amortization. Nonetheless, the corporation anticipates adjusted diluted net earnings per common share to range between $7.70 and $7.80 for the year. The forecast indicates a modest expectation for non-GAAP core revenue growth, projected at low single digits.

Future Prospects

Danaher is set to discuss its third quarter results and provide a financial outlook for both the fourth quarter and the entirety of 2025 during an upcoming investor conference call. This event promises to offer insights into the company’s strategic forecasts and the underlying assumptions driving their projections. Investors and stakeholders are invited to participate in the conference call beginning at 8:00 a.m. ET, with access available through Danaher’s investor relations website.

This quarter’s financial results solidify Danaher’s reputation as a leader in life sciences and diagnostics innovation. The company maintains its dedication to harnessing science and technology to tackle pressing healthcare challenges, a commitment that has guided their recent performance and ongoing future investments.

With approximately 63,000 associates globally, Danaher continues to improve the quality of life for billions through advanced science and technology. Their continued focus on innovation and operational excellence underscores their capacity to deliver sustainable healthcare solutions while maintaining a strong financial footing.

For more detailed information, including the Q3 earnings call replay, please visit Danaher’s Investor Relations.

Conclusion

Danaher Corporation's third quarter performance reflects a well-executed strategy that emphasizes growth and innovation. As the company moves forward, stakeholders can expect a continued focus on driving value and addressing the evolving challenges within the healthcare sector.